Search results for " Metastasis."

showing 10 items of 617 documents

Prognostic implications of extranodal extension in node-positive squamous cell carcinoma of the vulva: A systematic review and meta-analysis

2016

Squamous cell carcinoma (SCC) of the vulva is the fourth most common gynecological cancer, usually staged with the TNM or FIGO systems. Since 2009, FIGO staging has taken the extranodal extension (ENE) of lymph node metastases into account. ENE is defined as the spread of a lymph node metastasis into surrounding soft tissue. Although the TNM and FIGO systems acknowledge the importance of ENE in SCC, no comprehensive studies have analyzed the prognostic impact of this parameter. We therefore queried the PubMed and SCOPUS databases from their inception up until 04/01/2015, adopting no language restrictions: all prospective studies reporting on prognostic parameters in patients with vulvar SCC…

Oncologymedicine.medical_specialtyExtranodal metastasisVulva03 medical and health sciences0302 clinical medicineInternal medicineExtranodal extensionmedicineHumans030212 general & internal medicineProspective cohort studyLymph nodeGynecologyVulvar neoplasmVulvar NeoplasmsVulvar cancerbusiness.industryENE; Extranodal extension; Extranodal metastasis; Vulvar cancer; Oncology; SurgeryHazard ratioVulvar cancerENE; Extranodal extension; Extranodal metastasis; Vulvar cancermedicine.diseasePrognosisExtranodal metastasimedicine.anatomical_structureOncology030220 oncology & carcinogenesisMeta-analysisRelative riskCarcinoma Squamous CellENEFemaleSurgeryLymph Nodesbusiness
researchProduct

Receptor activator of NF-kB (RANK) expression associates with bone metastasis in breast carcinomas.

2010

Oncologymedicine.medical_specialtyHistologyPhysiologyActivator (genetics)business.industryEndocrinology Diabetes and MetabolismInternal medicinemedicineBone metastasisbusinessmedicine.diseaseReceptorBone
researchProduct

Efficacy of zoledronic acid in patients with colorectal cancer metastatic to bone

2011

Oncologymedicine.medical_specialtyHistologyPhysiologybusiness.industryColorectal cancerEndocrinology Diabetes and MetabolismBone metastasismedicine.diseaseZoledronic acidInternal medicinemedicineIn patientbusinessmedicine.drugMetastatic colon cancerBone
researchProduct

Extranodal extension of nodal metastases is a poor prognostic moderator in non-small cell lung cancer: a meta-analysis

2018

Extranodal extension (ENE) of nodal metastasis is defined as the extension of metastatic cells through the nodal capsule into the perinodal tissue. This morphological parameter, recently proposed as an important prognostic factor in different types of malignancy, has not been included in the TNM staging system for non-small cell lung cancer (NSCLC). In this systematic review with meta-analysis, we weighted the prognostic role of ENE in patients with lymph node-positive NSCLC. Two independent authors searched SCOPUS and PubMed through 28 February 2017. Prospective and retrospective studies on NSCLC, comparing patients with presence of ENE (ENE+) ENE+) vs. only intranodal extension (ENE–) and…

Oncologymedicine.medical_specialtyLung NeoplasmsExtracapsular; Extranodal; Lung cancer; Metastasis; NSCLC; PrognosisTNM staging systemNSCLCMalignancyMetastasisPathology and Forensic MedicineMetastasis03 medical and health sciences0302 clinical medicineCarcinoma Non-Small-Cell LungInternal medicinemedicine030212 general & internal medicineLung cancerMolecular BiologyEne reactionLung cancer . NSCLC . Prognosis . Extranodal . Extracapsular . MetastasisExtracapsularbusiness.industryHazard ratioRetrospective cohort studyCell BiologyGeneral MedicinePrognosismedicine.diseaseLymphatic Metastasis030220 oncology & carcinogenesisRelative riskExtranodalLymph NodesLung cancerNeoplasm Recurrence Localbusiness
researchProduct

What is the prognostic importance of lymphovascular space invasion in the absence of lymph node metastasis for early-stage endometrial cancer?

2021

Objective: The aim of this study is to analyze the prognostic role of lymph-vascular space invasion (LVSI), evaluated in a semi-quantitative fashion on prognosis of early stage, low risk endometrial cancer (EC). Methods: We enrolled patients who underwent surgery for endometrial cancer between 2003 and 2018 in two referral cancer center. All patients had endometrioid EC, G1–G2, with myometrial invasion <50%, and no lymph-node involvement. LVSI was analyzed in a semi-quantitative way, according to a 3-tiered scoring system in absent, focal and substantial. Results: Among 524 patients, any positive LVSI was found in 57 patients (10.9%) with focal LVSI (n=35, 6.7%) and substantial LVSI (n=2…

Oncologymedicine.medical_specialtyMultivariate analysisLymph node metastasisEndometrial Cancer03 medical and health sciences0302 clinical medicineText miningInternal medicineMedicineHumansRisk factorStage (cooking)Neoplasm MetastasisLetter to the EditorUnivariate analysis030219 obstetrics & reproductive medicineEndometrial Cancer; Neoplasm Metastasis; Prognostic FactorsEndometrial Cancer Neoplasm Metastasis Prognostic Factorsbusiness.industryPrognostic FactorsEndometrial cancerHazard ratioCancerObstetrics and GynecologyGeneral Medicinemedicine.diseasePrognosisLymphovascularEndometrial NeoplasmsSettore MED/40 - GINECOLOGIA E OSTETRICIAOncology030220 oncology & carcinogenesisLymphatic MetastasisLymph Node ExcisionFemaleLymphNeoplasm Recurrence LocalbusinessCarcinoma EndometrioidJournal of gynecologic oncology
researchProduct

Metástasis hipofisarias de tumores sólidos: 2 casos de diferente presentación

2019

Oncologymedicine.medical_specialtyNutrition and Dieteticsbusiness.industryEndocrinology Diabetes and Metabolismmedicine.diseaseMetastasisEndocrinologyText miningInternal medicineDiabetes mellitusmedicinePituitary metastasisPresentation (obstetrics)businessEndocrinología, Diabetes y Nutrición
researchProduct

Stage IV breast cancer: a population-based study about prognostic factors according to HER2 and HR status

2015

International audience; We aim to describe trends in net survival (NS) and to assess the prognostic factors among women with de novo metastatic breast cancer (MBC) according to human epidermal growth factor receptor 2 (HER2) and hormone receptor (HR) status. Data on women suffering from de novo MBC and diagnosed from 1998 to 2009 were provided by the Côte-d'Or breast cancer registry. NS was described using the Pohar Perme estimator and prognostic factors were investigated in a generalised linear model. We identified 232 patients (mean age = 64.7). Median NS was 29.2 months, 1- and 5-year NS were 76% and 26% respectively. The survival trend in patients with HER2-positive tumours who did not …

Oncologymedicine.medical_specialtyReceptor ErbB-2Antineoplastic AgentsBreast NeoplasmsTriple Negative Breast NeoplasmsLower riskBreast cancerTrastuzumabInternal medicinemedicineHumansNeoplasm Metastasisskin and connective tissue diseasesAgedNeoplasm StagingGynecologyregisterbusiness.industryCarcinoma Ductal BreastAge FactorsAbsolute risk reductionhormone receptorsCancerTriple Negative Breast NeoplasmsMiddle AgedTrastuzumabHER2 receptorsPrognosismedicine.diseaseMetastatic breast cancerConfidence interval3. Good healthpopulation-basedCarcinoma LobularReceptors EstrogenOncologyLinear ModelsFemalemetastatic breast cancernet survivalReceptors Progesteronebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologymedicine.drug
researchProduct

The treatment of advanced gastric cancer: current strategies and future perspectives.

2008

Oncologymedicine.medical_specialtybusiness.industryAdvanced stageCancerHematologyAdvanced gastric cancermedicine.diseasePrognosisGastroenterologyOncologyStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansNeoplasm MetastasisbusinessStomach cancerForecastingAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Preliminary Results of Two Eortc Randomized Trials in Previously Untreated Patients with Advanced T3 — T4 Prostatic Cancer

1983

At the end of 1976 and the beginning of 1977 respectively, the EORTC Genito-Urinary Tract Cancer Cooperative Group started two randomized phase III protocols in previously untreated patients with advanced T3–4 prostatic cancer (1–3). The first trial, 30762, compared Stilboestrol and Estracyt, while the second, 30761, was a randomized comparison of Stilboestrol, Cyproterone Acetate and Medroxyprogesterone Acetate. Both trials have now been closed to patient entry and the principal endpoints of the studies analyzed. This paper will present the interim results which have emerged from these two studies.

Oncologymedicine.medical_specialtybusiness.industryBone metastasisCyproterone acetateCancermedicine.diseaselaw.inventionCardiovascular deathchemistry.chemical_compoundchemistryRandomized controlled triallawInternal medicinemedicineMedroxyprogesterone acetateCooperative groupbusinessmedicine.drug
researchProduct

Current challenges in metastasis: Disseminated and circulating tumor cells detection

2014

Metastatic dissemination of the primary tumor is responsible for the majority of cancer-related morbidity and mortality. Detection of disseminated tumor cells in the bone marrow and circulating tumor cells in the peripheral blood is associated with early metastatic recurrence in cancer. Circulating tumor cells (CTCs) shed from the site of disease in metastatic or primary tumor that can be recognized and enriched in the peripheral blood of cancer patients. The detection of rare circulating tumor cells (CTC) is an objective of numerous oncologists' researches. Circulating tumor cells have the potential to help to detect cancer recurrence at its earlier stage, determine therapy resistance befo…

Oncologymedicine.medical_specialtybusiness.industryImmunologyCancerGeneral MedicineDiseaseNeoplastic Cells Circulatingmedicine.diseasePrimary tumorMetastasisClinical trialmedicine.anatomical_structureCirculating tumor cellNeoplasmsInternal medicinemedicineHumansImmunology and AllergyBone marrowNeoplasm MetastasisNeoplasm Recurrence LocalStage (cooking)businessHuman Antibodies
researchProduct